

**REMARKS**

Claims 1-19 are pending in the subject application. Claims 5 and 15 are subject to a species election.

In the August 27, 2003 Office Action, the Examiner required restriction under 35 U.S.C. § 121 and 372 to elect a single disclosed species of administration route. The administration routes listed in claims 5 and 15 are:

1. aerosolization
2. intravenous injection
3. oral
4. intraperitoneal
5. intranasal
6. topical
7. transmucosal

Applicants elect the route of intravenous injection administration with traverse. Further, this species election is without traverse to the extent that it is understood that (a) the requirement will be withdrawn upon the finding of an allowable genus; and (b) any species withdrawn from consideration will be transferred to the elected subject matter unless it is found patentably distinct from the elected invention.

*In re: Scheule et al.*  
*USSN: 09/890,712*  
*Filed: August 2, 2001*  
*Page 3*

**CONCLUSION**

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

10/2/03

Date

Elizabeth Lassen

Elizabeth Lassen

Attorney for Applicants

Registration No. 31,845

Telephone: (508) 270-2553

Facsimile: (508) 872-5415

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, Massachusetts 01701-9322